Welcome to our dedicated page for Fibrobiologics SEC filings (Ticker: FBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. reports that its board of directors approved an amendment and restatement of the company’s Bylaws on April 16, 2026. The change revises Section 2.07 to lower the quorum requirement for stockholder meetings from a majority of the voting power to one-third of the voting power.
The revised section keeps existing provisions that allow the meeting chair or stockholders present to adjourn meetings if a quorum is not reached and confirms that once a quorum is established, it is not lost by subsequent withdrawal of votes. The company filed its Second Amended and Restated Bylaws as an exhibit.
FibroBiologics, Inc. filed an amended current report to correct an omitted item number, without changing any prior disclosures. The company highlights a Sublease Buyout Agreement that ended its Webster, Texas sublease effective April 2, 2026, ahead of the original November 30, 2027 expiration.
FibroBiologics resolved all remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent. This move follows the 2025 opening of a new laboratory facility with over 10,000 square feet of lab and office space and supports consolidating operations. The company also updates its principal executive office address to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. Schedule 13G shows Lind Global Fund III LP and related reporting persons beneficially own 230,234 shares, representing 4.99% of common stock. The filing explains the position reflects 157,956 shares plus 540,536 warrants whose conversion is contractually limited to avoid ownership above 4.99%.
FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date. The company made a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent.
The change follows FibroBiologics’ 2025 opening of a new state-of-the-art laboratory facility with over 10,000 square feet of lab and office space and supports its consolidation of operations. The company’s principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. approved a capital change by implementing a one-for-twenty reverse stock split of its common stock. The Certificate of Amendment became effective at 12:01 a.m. Eastern Time on March 30, 2026, converting every 20 issued and outstanding common shares into 1 share.
No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share. The reverse split proportionately adjusts shares available under the equity incentive plan and existing options and warrants, but does not change the common stock’s par value, authorized share count, or the Nasdaq trading symbol FBLG.
FibroBiologics, Inc. completed a best-efforts public offering of 2,272,728 shares of common stock or equivalents and accompanying warrants, raising approximately $3 million in gross proceeds at a combined price of $1.32 per share and warrant. Net proceeds were about $2.5 million after fees, and are earmarked for working capital and general corporate purposes.
Investors also received warrants to purchase up to 2,272,728 additional shares at $1.32 per share, exercisable only after stockholder approval and expiring five years after that approval. If fully exercised for cash, these warrants could provide roughly $3 million in additional gross proceeds. Pre-funded warrants, issued at $1.31999 with a $0.00001 exercise price, are immediately exercisable and do not expire, subject to 9.99% beneficial ownership limits, while the other warrants and placement agent warrants carry a 4.99% ownership cap.
FibroBiologics is offering 1,028,788 shares of common stock, 1,243,940 pre-funded warrants and accompanying warrants to purchase up to 2,272,728 shares, at a combined public offering price of $1.32 per share plus warrant. Each public Warrant has an exercise price of $1.32 and is exercisable only after the effective date of the Warrant Stockholder Approval. Pre-Funded Warrants are exercisable for $0.00001 per share and are issued to limit single‑holder ownership above 4.99% (or electively 9.99%). The offering contemplates Placement Agent compensation including 159,091 Placement Agent Warrants and assumes delivery in a single closing. The prospectus gives effect to a 1-for-20 reverse stock split effective March 30, 2026, and states estimated net proceeds of approximately $2.5 million assuming full cash exercise of the Pre-Funded Warrants. The company remains listed on Nasdaq under FBLG and is taking these actions while seeking to regain compliance with Nasdaq bid-price requirements.
FibroBiologics, Inc. is registering up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants and related warrants in a best efforts public offering. Each share or pre-funded warrant is sold with a warrant, at an assumed combined price of $4.40. The company estimates net proceeds of about $4.3 million, intended for working capital and general corporate purposes. A 1-for-20 reverse stock split effective March 30, 2026 will reduce outstanding common shares from 70,256,883 to approximately 3,512,845, mainly to help regain Nasdaq bid-price compliance. The offering has no minimum size, may close with reduced proceeds and will cause immediate dilution for new investors.
FibroBiologics, Inc. filed Amendment No. 1 to its 2025 annual report to add the previously omitted Part III sections on directors, executive officers, compensation, security ownership, related‑party transactions and auditor fees. The company states the amendment does not change any prior financial results or other disclosures in the original 2025 report.
FibroBiologics, Inc. updated the compensation of its Chief Financial Officer. On March 4, 2026, the board’s Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026. His target for annual non‑equity incentive compensation remains at 40% of base salary.